Luye Group 
Welcome,         Profile    Billing    Logout  
 36 Products   29 Diseases   36 Products   123 Trials   3033 News 


«12...1415161718192021222324...3334»
  • ||||||||||  Goserelin extended release (LY 01005) / Luye Group
    Clinical, Journal, Video:  Laparoscopic uterine artery occlusion combined with uterine-sparing pelvic plexus block, and partial adenomyomectomy for adenomyosis: a video case report. (Pubmed Central) -  Oct 29, 2021   
    From the third day after the surgery, gonadotropin-releasing hormone (Goserelin Acetate Sustained-Release Depot,3.6mg each, subcutaneous injection, name of the enterprise: AstraZeneca UK Limited) was used every 4 weeks, with a total of 3 times...Clinically, it is difficult to be solved by medicine and traditional surgery, and hysterectomy is always performed for radical treatment. In this article, we introduce a new method which could control the dysmenorrhea and anemia through laparoscopic uterine artery occlusion (LUAO) combined with uterine-sparing pelvic plexus block, and partial adenomyomectomy for uterus perservation.
  • ||||||||||  Tukysa (tucatinib) / Seagen
    Acquired resistance to tucatinib is associated with EGFR amplification in HER2+ breast cancer (BC) models and can be overcome by a more complete blockade of HER receptor layer (Stars at Night 3/4) -  Oct 26, 2021 - Abstract #SABCS2021SABCS_815;    
    Materials and Methods : Our previously characterized HER2+ BT474 models with acquired resistance to lapatinib (L; LapR) or N (NrbR) (SABCS20-PD3-09), and our recently developed models of BT474 and SKBR3 with acquired resistance to T (TucaR) developed through long-term exposure to increasing doses of T (up to 200nM) and their naïve parental (P) were used...Further, the elevated pEGFR, pHER2, pHER3, pAKT, and pS6 levels in TucaR models were substantially suppressed by the EGFR-specific TKI gefitinib (G) (50, 500nM) or even further when combined with T (500 nM G+200nM T)...Whilst we previously reported that the LapR and NrbR cells were cross-resistant to T, the TucaR cells remained highly sensitive to the pan-HER TKIs N, poziotinib, and pyrotinib...Further, while resistance to L and N confers cross-resistance to T, resistance to T may be overcome using pan-HER TKIs or the combination of potent EGFR and HER2 inhibitors. Together, our findings hold crucial implications in light of the current treatment landscape of HER2+ BC, with a particular emphasis on the considerations to strategize the treatment sequence of currently available TKIs.
  • ||||||||||  ansofaxine ER (LY03005) / Luye Group
    Journal:  Pharmacological Characterization of Toludesvenlafaxine as a Triple Reuptake Inhibitor. (Pubmed Central) -  Oct 2, 2021   
    Plasma ODV exposure was proportionally related to the doses after oral dosing. These results suggest that toludesvenlafaxine is a triple reuptake inhibitor with relatively fast-acting antidepressant-like activity and good therapeutic profile including improvement of anhedonia and sexual function.
  • ||||||||||  utidelone (UTD1) / Beijing Biostar Technologies
    Journal, PARP Biomarker:  Utidelone inhibits growth of colorectal cancer cells through ROS/JNK signaling pathway. (Pubmed Central) -  Sep 19, 2021   
    Utidelone (UTD1), a novel microtubule stabilizing agent, is an epothilone B analogue which was produced by genetic engineering...Moreover, UTD1 inhibited tumor growth and was more effective and safer compared with paclitaxel and 5-FU in RKO xenograft in nude mice. Taken together, our findings first indicate that UDT1 inhibits tumor growth in CRC xenograft model and may be a promising agent for CRC treatment.